CMChristine J. Martin

Christine J. Martin

*This is an algorithmically generated author record based on publicly available information.

Christine J. Martin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Barrie Wilkinson

    Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.

    1 shared publication
  • Chrisostomos Prodromou

    Department of Biochemistry and Biomedicine, University of Sussex, Brighton BN1 9QG, UK

    1 shared publication
  • Iain R. Challis

    Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.

    1 shared publication
  • Isabelle Carletti

    Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.

    1 shared publication
  • Laurence H. Pearl

    Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RQ, UK

    1 shared publication
  • Matthew Gregory

    Biotica Technology Limited, Chesterford Research Park, Essex CB10 1XL, U.K., Section of Structural Biology, Chester Beatty Laboratories, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and CompChem Solutions, St. John’s Innovation Centre, Cowley Road, Cambridge CB4 0WS, U.K.

    1 shared publication

Latest Publications

  • Molecular Characterization of Macbecin as an Hsp90 Inhibitor

    by Christine J. Martin, Sabine Gaisser, Iain R. Challis, Isabelle Carletti, Barrie Wilkinson, Matthew Gregory, Chrisostomos Prodromou, S. Mark Roe, Laurence H. Pearl, Susan M. Boyd, et al.

    Macbecin compares favorably to geldanamycin as an Hsp90 inhibitor, being more soluble, stable, more potently inhibiting ATPase activity (IC50 = 2 µM) and binding with higher affinity (Kd = 0.24 µM). Structural studies reveal significant differences in their Hsp90 binding characteristics, and macbecin-induced tumor cell growth inhibition is accompanied by characteristic degradation of Hsp90 client proteins. Macbecin significantly reduced tumor growth rates (minimum T/C: 32%) in a DU145 murine xenograft. Macbecin thus represents an attractive lead for further optimization.